Edition:
United Kingdom

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

283.20SEK
17 Dec 2018
Change (% chg)

-3.80kr (-1.32%)
Prev Close
287.00kr
Open
288.20kr
Day's High
288.20kr
Day's Low
279.60kr
Volume
90,804
Avg. Vol
201,348
52-wk High
349.40kr
52-wk Low
196.80kr

Latest Key Developments (Source: Significant Developments)

EGM Resolves To Change Hansa Medical's Company Name To Hansa Biopharma
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Hansa Medical AB ::BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF HANSA MEDICAL AB (PUBL).EXTRAORDINARY GENERAL MEETING RESOLVED TO CHANGE HANSA MEDICAL'S COMPANY NAME TO HANSA BIOPHARMA AB.  Full Article

Hansa Medical Receives Positive Opinion For Orphan Drug Designation In The EU
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Hansa Medical AB ::HANSA MEDICAL RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR IMLIFIDASE FOR ANTI-GBM DISEASE.  Full Article

Hansa Medical: FDA Fast Track Designation For Imlifidase For Transplantation
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Hansa Medical AB ::HANSA MEDICAL RECEIVES FDA FAST TRACK DESIGNATION FOR IMLIFIDASE FOR TRANSPLANTATION.  Full Article

Hansa Medical Reports Positive Final Top Line Results From Two Phase 2 Studies Of Imlifidase For Kidney Transplantation
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Hansa Medical AB ::HANSA MEDICAL REPORTS POSITIVE FINAL TOP LINE RESULTS FROM TWO PHASE 2 STUDIES OF IMLIFIDASE FOR KIDNEY TRANSPLANTATION.SAYS IMLIFIDASE MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN BOTH STUDIES.SAYS TREATMENT WITH IMLIFIDASE ENABLES HIGHLY SENSITIZED PATIENTS TO RECEIVE LIFESAVING TRANSPLANTS.HANSA MEDICAL PLANS TO SUBMIT BLA AND MAA FILINGS IN Q4 2018 OR Q1.RESULTS DEMONSTRATE FAVORABLE SAFETY PROFILE AFTER SIX-MONTH FOLLOW-UP.  Full Article

Hansa Medical Q2 Operating Loss Widens To SEK 58.8 Million
Thursday, 19 Jul 2018 

July 19 (Reuters) - Hansa Medical AB ::Q2 NET REVENUE SEK 0.9 MILLION VERSUS SEK 0.7 MILLION YEAR AGO.Q2 OPERATING LOSS SEK 58.8 MILLION VERSUS LOSS SEK 44.9 MILLION YEAR AGO.  Full Article

Hansa Medical: IdeS Receives Orphan Drug Designation From FDA
Monday, 9 Jul 2018 

July 9 (Reuters) - Hansa Medical AB ::HANSA MEDICAL LEAD CANDIDATE IMLIFIDASE (IDES) GRANTED ORPHAN DRUG DESIGNATION BY THE FDA FOR ANTI-GBM ANTIBODY DISEASE.  Full Article

Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million
Wednesday, 25 Apr 2018 

April 25 (Reuters) - HANSA MEDICAL AB ::Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO.Q1 NET SALES SEK 588,000 VERSUS SEK 1.1 MILLION YEAR AGO.  Full Article

‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Hansa Medical Ab ::‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​.HANSA MEDICAL -COMMISSIONED EVERCORE, RBC CAPITAL AND SEB, TO INVESTIGATE POSSIBILITY OF UNDERTAKING NEW ISSUE OF SHARES TO INSTITUTIONAL INVESTORS.‍INTENDS TO USE PROCEEDS FROM DIRECTED ISSUE TO FUND CONTINUED DEVELOPMENT OF COMPANY'S EXISTING PORTFOLIO​.  Full Article

Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - HANSA MEDICAL AB ::Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO.Q3 NET REVENUE SEK ‍​678,000 VERSUS SEK 0.9 MILLION YEAR AGO.  Full Article

Hansa Medical: sudden death of CEO Göran Arvidson​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - HANSA MEDICAL AB :‍ANNOUNCES SUDDEN DEATH OF CEO GÖRAN ARVIDSON​.‍CHAIRMAN ULF WIINBERG WILL SERVE AS ACTING CEO.‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​.  Full Article

BRIEF-Hansa Medical: SEK 453 Mln Before Issue Costs In New Issue

* ANNOUNCED ON WEDNESDAY CLOSING OF DIRECTED SHARE ISSUE CONSISTING OF 1,776,765 ORDINARY SHARES AT PRICE OF SEK 255 PER SHARE